Teradyne, Inc., a technology company headquartered in North Reading, Massachusetts and listed on NASDAQ under the ticker TER, is scheduled to announce its fourth quarter earnings after the market closes on Monday, February 2.
Current analyst consensus predicts that Teradyne will report earnings of $1.36 per share for the quarter, representing a notable increase from $0.95 per share reported in the same period last year. Revenue expectations are similarly elevated, with forecasts averaging approximately $970.46 million, compared to $752.88 million earned in the previous year’s fourth quarter. These data points are derived from Benzinga Pro analytics.
Notably, on January 29, Teradyne and MultiLane made a joint public announcement establishing a new joint venture entitled MultiLane Test Products. This strategic move is likely to impact the company's operational profile and market positioning.
In the immediate aftermath of this announcement, Teradyne's stock experienced a 4.3% decline, closing at $241.05 on the previous Friday’s trading session, reflecting investor caution ahead of the earnings report.
Investor interest in Teradyne has led to several recent analyst ratings and price target revisions by some of the most accurate financial analysts tracked by Benzinga:
- Brian Chin from Stifel retained a Buy rating and adjusted his price target upwards from $270 to $280 as of January 30, 2026. Chin's historical rating accuracy stands at 84%.
- Timothy Arcuri of UBS maintained a Buy rating and raised his price target from $200 to $275 on January 26, 2026. Arcuri also holds an 84% accuracy rating.
- Vivek Arya from B of A Securities continued to recommend buying the stock and increased his price target from $250 to $260 on January 22, 2026; his accuracy in prior calls is 82%.
- James Schneider at Goldman Sachs upgraded Teradyne from a Sell to a Buy rating and substantially lifted his price target from $148 to $230 on December 16, 2025, with an accuracy rate of 65% over time.
- Atif Malik of Citigroup preserved his Buy stance and boosted his price target from $117 to $215 on November 12, 2025. Malik’s rating accuracy is 85%.
The series of price target increases and positive rating confirmations across different firms indicate growing confidence among these analysts regarding Teradyne’s prospects in the upcoming reporting period.
Benzinga's platform provides access to up-to-date analyst rankings and allows users to sort by various parameters such as stock ticker symbol, company name, analyst firm name, or rating changes, facilitating investor research.
Teradyne's stock performance as of the close of the last trading session reflected a 1.06% decline, with shares trading at $238.49. According to Benzinga's proprietary rankings, the stock exhibits momentum scores of 96.59 and quality scores of 82.63. However, value metrics are comparatively low with a score of 9.00. These rankings help investors gauge the stock’s performance and relative valuations over short, medium, and long terms.
As Teradyne approaches its earnings announcement, investors and analysts alike are monitoring not only reported financial results but also the potential impact of its new joint venture alongside longer-term strategic implications. The market’s reaction to the forthcoming earnings release will offer further insight into the company's growth trajectory and operational execution moving forward.
Key Points:
- Teradyne is anticipated to report fourth quarter earnings per share of $1.36, a substantial increase from $0.95 in the prior year period.
- Revenue estimates stand at approximately $970.46 million, up from $752.88 million in the corresponding quarter last year.
- A newly formed joint venture, MultiLane Test Products, was announced in late January, potentially influencing Teradyne's future business prospects.
- Several top-rated analysts have upgraded price targets for Teradyne shares, reflecting increased confidence ahead of the earnings report.
Risks and Uncertainties:
- Stock price volatility has been observed following recent corporate announcements, including a significant decline soon after the joint venture disclosure.
- Analyst forecasts and price targets are subject to revision and can vary widely, indicating an inherent uncertainty in projecting earnings outcomes.
- The actual impact of the newly created joint venture on Teradyne's financials and market position remains uncertain until disclosed in detail.
- Market conditions and investor sentiment leading into and following the earnings release may cause unpredictable share price movements.
Disclosure: The information contained herein is intended solely for informational purposes and does not constitute investment advice or a recommendation to buy or sell securities.